Irish medical journal · 2026
Trends in the Dispensing of Adult ADHD Medications.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Maher A, Cahill M, Murphy A W, Molloy G
Аннотация
AIMS: To examine patterns of stimulant ADHD medications to adults in Ireland between 2015 and 2024, under community drug schemes. We aimed to describe changes over time across age groups, demographic characteristics, and geographic areas.
METHODS: Dispensing data were obtained from the Irish Primary Care Reimbursement Service, namely prescriptions reimbursed through General Medical Services scheme and Drug Payment scheme. Dispensing volumes and patient numbers for NICE-recommended first-line agents, methylphenidate and lisdexamfetamine, were analysed using a retrospective repeated cross-sectional design.
RESULTS: The number of recorded dosage units of both medications increased by ~211% (700,574 to 2,217,634) between 2015 and 2024. Units of lisdexamfetamine rose by ~504% (59,088 to 356,641) between 2020 and 2023. The number of patients also increased during this time (3,377 to 13,966). Adults aged 16-34 years experienced the largest growth. By 2024, dispensings among females had increased to levels approaching those observed in males. Regional patient variation was evident, with largest increases observed in North Cork, Waterford, and Cork-South Lee.
DISCUSSION: Adult ADHD pharmacotherapy in Ireland appears to have increased over the past decade, which could reflect evolving service provision. Demographic and regional variation could underscore the need for equitable expansion of adult ADHD assessment and treatment services.
METHODS: Dispensing data were obtained from the Irish Primary Care Reimbursement Service, namely prescriptions reimbursed through General Medical Services scheme and Drug Payment scheme. Dispensing volumes and patient numbers for NICE-recommended first-line agents, methylphenidate and lisdexamfetamine, were analysed using a retrospective repeated cross-sectional design.
RESULTS: The number of recorded dosage units of both medications increased by ~211% (700,574 to 2,217,634) between 2015 and 2024. Units of lisdexamfetamine rose by ~504% (59,088 to 356,641) between 2020 and 2023. The number of patients also increased during this time (3,377 to 13,966). Adults aged 16-34 years experienced the largest growth. By 2024, dispensings among females had increased to levels approaching those observed in males. Regional patient variation was evident, with largest increases observed in North Cork, Waterford, and Cork-South Lee.
DISCUSSION: Adult ADHD pharmacotherapy in Ireland appears to have increased over the past decade, which could reflect evolving service provision. Demographic and regional variation could underscore the need for equitable expansion of adult ADHD assessment and treatment services.